title: A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination.
abstract: Clinical studies of WT1-targeted cancer vaccine are being performed. However, WT1-specific Th response in cancer patients remains unclear. Using quantitative real-time RT-PCR, we investigated IFN-gamma and IL-10 mRNA expression from Th cells by stimulation with helper peptide WT1(332). Seventeen patients, of whom 10 had achieved stable disease and the remaining 7 had progressive disease, were weekly vaccinated with WT1 CTL epitope (modified WT1(235)) and examined for WT1(332)-specific Th response. A clear correlation between WT1(332)-specific Th response and clinical response was observed at 4 weeks post-vaccination. In patients who responded, a clear inverse correlation between IL-10-type and IFN-gamma-type WT1(332)-specific Th response was detected at pre- and 4 weeks post-vaccination, and the shift of the Th response from IL-10-type dominancy at early phase to IFN-gamma-type dominancy at late phase was observed. From this study we concluded that occurrence of WT1(332)-specific Th response could predict good clinical response of WT1 CTL epitope vaccination.
authors.affiliation: Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, 1-7, Yamada-Oka, Suita City, Osaka 565-0871, Japan.
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Fujiki
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Oka
authors.forename: Mai
authors.initials: M
authors.lastname: Kawakatsu
authors.forename: Akihiro
authors.initials: A
authors.lastname: Tsuboi
authors.forename: Yukie
authors.initials: Y
authors.lastname: Tanaka-Harada
authors.forename: Naoki
authors.initials: N
authors.lastname: Hosen
authors.forename: Sumiyuki
authors.initials: S
authors.lastname: Nishida
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Shirakata
authors.forename: Hiroko
authors.initials: H
authors.lastname: Nakajima
authors.forename: Naoya
authors.initials: N
authors.lastname: Tatsumi
authors.forename: Naoya
authors.initials: N
authors.lastname: Hashimoto
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Taguchi
authors.forename: Satsuki
authors.initials: S
authors.lastname: Ueda
authors.forename: Norio
authors.initials: N
authors.lastname: Nonomura
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takeda
authors.forename: Toshinori
authors.initials: T
authors.lastname: Ito
authors.forename: Akira
authors.initials: A
authors.lastname: Myoui
authors.forename: Shuichi
authors.initials: S
authors.lastname: Izumoto
authors.forename: Motohiko
authors.initials: M
authors.lastname: Maruno
authors.forename: Toshiki
authors.initials: T
authors.lastname: Yoshimine
authors.forename: Shinzaburo
authors.initials: S
authors.lastname: Noguchi
authors.forename: Akihiko
authors.initials: A
authors.lastname: Okuyama
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kawase
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Oji
authors.forename: Haruo
authors.initials: H
authors.lastname: Sugiyama
mesh_terms: D000328:Adult; D000368:Aged; D019496:Cancer Vaccines / Q000276:immunology*; D018984:Epitopes, T-Lymphocyte; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000235:genetics; D016753:Interleukin-10 / Q000235:genetics; D008297:Male; D008875:Middle Aged; D012333:RNA, Messenger / Q000032:analysis; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*; D014611:Vaccination; D025721:WT1 Proteins / Q000276:immunology*
chemical_list: D019496:Cancer Vaccines; D018984:Epitopes, T-Lymphocyte; D012333:RNA, Messenger; D025721:WT1 Proteins; D016753:Interleukin-10; D007371:Interferon-gamma